OnKure Therapeutics, Inc. Class A Common Stock
OKUROnKure Therapeutics, Inc. Class A (OKUR) is a biopharmaceutical company focused on developing innovative cancer therapies. It specializes in creating targeted treatments aimed at improving outcomes for patients with various malignancies, utilizing cutting-edge research and technology to address unmet medical needs in oncology.
$2.60 +0.02 (0.78%)
Company News
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Therapeutics announced positive preliminary data from its first-in-human trial of OKI-219, a PI3Kα inhibitor, showing good tolerability and favorable pharmacokinetics. The company plans to initiate a combination trial with fulvestrant in the second half of 2025.
